Testing a new antibody for hepatitis B safety
Treatments studied
Part of Digestive system, Infections clinical trials.
This trial tests an experimental antibody treatment for people with chronic hepatitis B who have been on antiviral medication for at least 6 months. It aims to see if the antibody is safe and can help control the virus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have had hepatitis B for at least 6 months and have been on antiviral pills for at least 6 months.
- Your hepatitis B virus is undetectable in your blood (DNA below the test's limit).
- You have not been treated with any hepatitis B antibody before.
- You do not have other active infections like HIV, hepatitis C, or hepatitis delta.
- You do not have advanced liver scarring (fibrosis) or certain liver lesions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether a hepatitis B vaccine (with an added ingredient to boost the immune response) can safely help people with long-term hepatitis B who are already on antiviral therapy. It is mainly looking at safety and how the immune system responds.
This early-stage trial tests whether a new monoclonal antibody (a lab-made protein that fights viruses) is safe and effective in people with chronic hepatitis D infection. Hepatitis D only occurs in people who also have hepatitis B, and this new treatment may help control the virus.
This study tests a new antibody treatment (VIR-3434) for chronic hepatitis B. It aims to see if the antibody can help your immune system control the virus, potentially allowing you to stop your current antiviral medication later.
This trial tests a new treatment (GST-HG131&141 tablets) versus a placebo for people with chronic hepatitis B. It aims to see if the treatment can better control the virus in those already on stable therapy.
This trial tests a new drug called GST-HG141 for people with chronic hepatitis B whose virus is still active despite taking standard antiviral pills. It aims to see if the new drug can better control the virus.
This study tests a new medicine called AHB-137 for people with chronic hepatitis B who are HBeAg negative and currently on antiviral therapy. The goal is to see if it can help control the virus better or allow you to stop your current medication safely.
Hear when a new Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.